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Abstract 
Background: According to the Response Evaluation Criteria in Solid Tumors (RECIST) 
classification, progressive disease (PD) is defined as target lesion growth (TLG), unequivocal 
non-target lesion growth (NTLG), or new lesion appearance (NLA). The prognostic impact of the 
components of PD in tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma 
(mRCC) remains unknown. 
Objective: We retrospectively evaluated the prognostic impact of these PD components on 
survival in patients with mRCC after first-line TKI therapy. 
Patients and Methods: Patients were divided into three groups (TLG, NTLG and NLA) based on 
the components of PD. Progression-free survival (PFS) and overall survival (OS) after first-line 
TKI therapy were compared to PD components using the Kaplan-Meier method and log-rank test. 
The predictive impact of the PD components was evaluated using multivariate analyses.  
Results: Among the 116 patients included, 80 (69.0%) were classified to the TLG group, 18 
(15.5%) to the NTLG group and 69 (58.6%) to the NLA group. The mean PFS and OS were 
shorter for patients with than without TLG (PFS, 7.1 vs. 11.6 months, respectively, p=0.0071; OS, 
18.2 vs. 25.5 months, respectively, p=0.0091). TLG was an independent predictor of PFS (hazard 
ratio [HR], 1.59; 95% confidence interval [CI], 1.02–2.51; p=0.0395) and OS (HR, 1.67; 95% CI, 
1.02–2.83; p=0.040). NTLG and NLA were not associated with survival. 
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Conclusions: In this retrospective single-center study, patients with TLG had a poor survival after 
first-line TKI therapy for mRCC. Thus, the components of PD influence patient prognosis.  
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Key points 
•  Patient survival after first-line tyrosine kinase inhibitor therapy for metastatic renal cell 
carcinoma differed according to the components of progressive disease. 
•  Target lesion growth was an independent predictor for poor survival in patients receiving 
first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. 
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1. Introduction 
The advent of molecular-targeted therapy has notably changed the treatment strategy for 
metastatic renal cell carcinoma (mRCC) [1-3]. According to current guidelines, tyrosine kinase 
inhibitor (TKI) therapy is preferred for most patients with mRCC [2, 4, 5]. The Response 
Evaluation Criteria in Solid Tumors (RECIST) is a gold standard for assessing the therapeutic 
efficacy of cancer treatments including TKI therapy [6]. Further, several prognosticators based on 
RECIST have been indicated in TKI therapy for mRCC [7-11].  
According to the RECIST v.1.1, progressive disease (PD) is defined as target lesion growth 
(TLG), unequivocal non-target lesions growth (NTLG) or new lesions appearance (NLA). Several 
studies have reported that oncological outcomes were significantly different among the three 
components of PD. Litiere et al. suggested that NTLG and NLA were worse prognostic factors in 
patients with breast, colon, and lung cancers [12]. Furthermore, Twelves et al. reported that NLA 
was significantly associated with a poor prognosis in metastatic breast cancer treated with 
chemotherapy [13]. It is important to understand the impacts of PD components on survivals as 
these can contribute to better prognostication and treatment planning. However, the prognostic 
impact of the components of PD in TKI therapy for mRCC remains unknown. Therefore, we 
retrospectively evaluated the prognostic impact of the components of PD in patients who received 
first-line TKI therapy for mRCC.  
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2. Materials and methods 
2.1 Patient selection 
In our department, 188 patients received first-line TKI therapy (106, sunitinib; 69, 
sorafenib; 13, pazopanib) between January 2007 and March 2017. Among these, we excluded 29 
patients who received first-line TKI at the end of follow-up, after continuous observation of their 
tumor response, and another 21 patients, in whom TKI therapy was discontinued due to adverse 
events. Of the remaining 138 patients who had PD after TKI therapy, 1 patient who had received 
prior cytokine therapy, 4 patients who received TKIs for only a short duration (i.e., < four weeks), 
and 17 patients who received hemodialysis or kidney transplantation, were excluded. Finally, 116 
patients were retrospectively evaluated (Electronic Supplementary Material 1). All patients 
experienced PD based on the RECIST ver. 1.1 after first-line TKI therapy initiation. 
 
2.2 Response criteria 
According to the RECIST ver. 1.1, we evaluated the tumor response for target lesions, non-
target lesions and new lesions, with each classification defined as follows [6]. TLG was defined 
as a ≥20% increase in the sum of diameters of target lesions, taking as the reference the smallest 
sum observed in the study. In addition to a relative increase of 20%, the sum had to demonstrate 
an absolute increase of at least 5 mm. Moreover, the unequivocal progression of existing non-
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target lesions (i.e. NTLG) and the appearance of new malignant lesions (i.e. NLA) were defined 
as disease progression. 
 
2.3 Study design and endpoint 
The Patients were divided into three groups according to PD components, namely the TLG, 
NTLG and NLA groups. The different components of PD were not mutually exclusive and 
categories could overlap in several cases.  
The endpoints of this study were progression-free survival (PFS) and overall survival (OS) 
after first-line TKI therapy initiation. PFS was defined as the time from first-line TKI initiation 
to the date of progression. OS was defined as the time from the start of first-line TKI initiation to 
death from any cause.  
 
2.4 Imaging methods and assessment 
Baseline imaging examinations, including plain or contrast-enhanced computed 
tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis, were 
performed within 28 days before the start of TKI therapy. Regular scans were also performed at 
every 8–12 weeks of therapy, according to the patient’s condition. One of the investigators (T.I.), 
who was blinded to all other clinical parameters and the patient outcomes, reviewed all images 
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for analysis.  
 
2.5 Protocols of tyrosine kinase inhibitor regimens 
The TKI regimens in our department have been previously described [14, 15]. The main 
agent for first-line TKI therapy is sunitinib. In the sunitinib regimen, we currently administer a 2-
week-on/1-week-off schedule, based on findings from our previous study [16]. Sunitinib is orally 
administered at a dose of 50 mg daily and modified according to patients’ condition. Based on 
previous research, for patients with a poor performance status or >80 years of age, either sorafenib 
or pazopanib were selected as these TKIs have better tolerability than sunitinib [17-20]. In the 
sorafenib regimen, 200 mg sorafenib is orally administered twice daily and increased up to 800 
mg within 2–4 weeks to reduce any acute dermatological reactions, with a continuous dosing 
schedule. In the pazopanib regimen, the drug is orally initiated once daily at a dose of 800 mg 
with continuous dosing. The dose is reduced to 600 mg and then to 400 mg according to the 
severity of adverse events. In all the regimens, the drugs are administered until PD is observed or 
intolerable adverse events occur. 
 
2.6 Statistical analysis 
Distributions of PFS and OS were calculated using the Kaplan-Meier method and compared 
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using the log-rank test. The median PFS and OS along with 95% confidence intervals (CI) were 
reported. Univariate and multivariate analyses using Cox proportional hazards regression models 
were used to identify predictors of survival. All analyses were performed using JMP software 
(version 12.1; SAS Institute, Cary, NC, USA) and differences were considered statistically 
significant at p-values <0.05. 
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3. Results 
3.1 Patient characteristics 
Eighty-two patients were men (70.7%) and the median patient age was 66.0 years. The most 
frequent pathological type was clear cell carcinoma (CCC) (n = 84, 72.4%). Sorafenib, sunitinib 
and pazopanib were administered as first-line TKI agents in 35 (30.2%), 73 (62.9%) and 8 (6.9%) 
patients, respectively. Among the 116 patients, 80 (69.0%) were classified to the TLG group, 18 
(15.5%) to the NTLG group, and 68 (58.6%) to the NLA group. Additionally, 43 and 36 patients 
had TLG alone and NLA alone, respectively, whereas no patients had NTLG alone. Furthermore, 
35 patients had overlapping components of PD. Among these 35 patients, two patients (1.7%) had 
TLG and NTLG, 17 patients (14.7%) TLG and NLA and 16 patients (13.8%) all three components. 
No patients had NTLG and NLA (Table 1). Electronic Supplementary Material 2 shows the PFS 
and OS of our entire study group, with a median PFS of 8.7 months and OS of 20.6 months.  
 
3.2 Progression-free survival according to the individual components of progressive disease 
Figure 1 shows the Kaplan-Meier curves of PFS after first-line TKI therapy according to 
the individual components of PD. Patients with TLG had a significantly shorter PFS compared to 
those without TLG (7.1 [95% CI :5.6–9.1] vs. 11.6 [95% CI: 6.3–15.1] months, p = 0.0071). 
Patients with NTLG had a significantly shorter PFS compared to those without NTLG (5.7 [95% 
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CI: 2.9–9.2] 9.0 [95% CI: 6.4–11.4] months, p = 0.0361). There was a significant difference in 
PFS between patients with and without NLA (7.1 [95% CI: 5.4–11.0] 9.1 [95% CI: 6.1–11.5] 
months, p = 0.225).  
 
3.3 Overall survival according to individual components of progressive disease 
Figure 2 shows the Kaplan-Meier curves of OS after first-line TKI therapy according to 
individual components of PD. Patients with TLG had a significantly shorter OS (TLG, median: 
18.2 [95% CI: 13.3–23.1] no TLG, 25.5 [95% CI: 20.3–not reached] months, p = 0.0091). Patients 
with NTLG did not demonstrate a significant difference in OS (NTLG, 14.0 [95% CI: 8.5–31.7] 
no NTLG, 21.7 [95% CI: 18.2–27.4] months, p = 0.113). Patients with NLA did not show a 
significant difference in OS (NLA, 19.3 [95% CI: 13.7–25.6] no NLA, 21.7 [95% CI: 14.5–30.6] 
months, p = 0.381).  
 
3.4 Progression-free survival and overall survival in patients with target lesion growth alone, new 
lesions appearance alone, and multiple components of progressive disease 
To exclude the potential influences of overlapping PD components, we compared survival 
among patients who had a single component. Figure 3 shows that patients who had TLG alone 
had a significantly shorter OS than those with NLA alone (20.4 [95% CI: 13.7–27.4] vs. 29.9 
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[95% CI: 21.0–not reached] months, p = 0.0212). However, a trend for a shorter PFS was observed 
in patients with TLG alone than NLA alone (7.3 [95% CI: 5.0–11.4] vs. 10.5 [95% CI: 6.1–15.1] 
months, p = 0.0759).  
      
3.5 Predictors of progression-free survival and overall survival 
As shown in Table 2, univariate analysis for PFS showed that TLG, compared to no TLG, 
was a significant predictor of shorter PFS (p = 0.0061). Additionally, female sex, non-CCC 
pathological type, absence of a prior nephrectomy, and poor risk, based on MSKCC risk 
classification, were also significant predictors for shorter PFS (p < 0.05 for all). Multivariate 
analysis for PFS identified TLG as an independent predictor of shorter PFS (hazard ratio [HR]: 
1.59, 95% CI: 1.02–2.51, p = 0.0395), in addition to the absence of a prior nephrectomy (HR: 
2.07, 95% CI: 1.13–3.61, p = 0.0182) and poor risk, based on MSKCC risk classification, (HR: 
3.22, 95% CI: 1.83–5.39, p = 0.0001).   
As shown in Table 3, univariate analyses identified TLG as a significant predictor of OS 
(HR: 1.90, 95% CI: 1.18–3.16, p = 0.0073). Additionally, female sex, non-CCC pathological type, 
the absence of a previous nephrectomy, poor risk, based on MSKCC risk classification, and 
multiple metastasis were also significant predictors of OS (p < 0.05 for all). Multivariate analyses 
identified TLG as an independent predictor of OS (HR: 1.67, 95% CI: 1.02–2.83, p = 0.04), in 
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addition to female sex (HR: 1.73, 95% CI: 1.06–2.78, p = 0.0299), non-CCC pathological type 
(HR: 1.99, 95% CI: 1.15–3.38, p = 0.0144), poor risk based on MSKCC risk classification (HR: 
2.74, 95% CI: 1.48–4.80, p = 0.0019), and multiple metastasis (HR: 2.19, 95% CI: 1.36–3.66, p 
= 0.0012).  
 
3.6 Overall survival after first-line therapy failure according to the components of progressive 
disease 
Further, to investigate whether TLG could affect prognosis after first-line therapy failure, 
we compared OS after first-line therapy failure between patients with and without TLG, as well 
as between patients with TLG alone and NLA alone. Consequently, patients with TLG had a 
significantly shorter OS after first-line therapy failure than those without TLG (8.3 [95% CI: 5.0–
9.9] vs. 16.8 [95% CI: 5.7–29.5] months, p = 0.0142) (Electronic Supplementary Material 3A). 
However, only a trend toward a shorter OS was identified in patients with TLG alone compared 
to NLA alone (8.3 [95% CI: 4.9–13.1] vs. versus 16.8 [95% CI: 5.7–29.5] months, p = 0.0773) 
(Electronic Supplementary Material 3B).  
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4. Discussion 
This study indicated that patients with TLG had a significantly poor PFS and OS and that 
patients with NTLG had a significantly poor PFS after first-line TKI therapy for mRCC. However, 
NLA was not significantly associated with PFS or OS. Multivariate analyses identified TLG as 
an independent predictive factor of PFS and OS. To the best of our knowledge, this is the first 
study evaluating the prognostic impact of components of PD after first-line TKI therapy for 
mRCC.  
Previous studies have reported that NLA or NTLG was associated with poor patient survival 
after cytotoxic chemotherapies or targeted therapies for non-urological cancer [12, 13, 21, 22]. 
Nevertheless, TLG was a significant factor for oncological outcomes in our analysis. This 
difference may have been caused by different types of cancers or corresponding treatments 
between molecular-targeted therapy and cytotoxic chemotherapy. That is, in some patients, it is 
difficult to evaluate the tumor response to targeted therapy for mRCC according to the RECIST 
because specific morphological changes, such as necrosis, cannot be accurately reflected [23-25]. 
Therefore, a difference of PD interpretation may affect the analyses of outcomes according to 
types of treatment.  
Regarding mRCC, Stein et al. showed that NTLG and NLA, and not TLG, were significant 
predictors of survival using data from RECORD-1 [26]. However, the significant associations of 
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NTLG or NLA were not observed in the intermediate term after treatment initiation (i.e., 14–18 
weeks) in their study. Therefore, the prognostic impact of the PD components may be strongly 
affected by the timing of PD. Stein et al. also indicated that poor OS could be predicted by the 
fastest growing target lesion [26]. Other studies also reported that early treatment failure was 
significantly associated with poor oncological outcomes [26-28]. Similarly, our previous data 
showed that slow tumor growth mediated by TKI therapy was associated with a favorable 
prognosis [14, 15]. Indeed, in the present study, 18 patients experienced PD within the initial three 
months after therapy initiation and their OS was significantly poorer compared to the other 
patients. Further, TLG was observed in 15 of these patients. In all, TLG was associated with early 
treatment failure and resulted in poor survival compared to the other PD components.  
Importantly, the patients with TLG had a significantly shorter OS after first-line TKI 
therapy failure (Electronic Supplementary Material 3). In this study, conventional TKI or 
mammalian target of rapamycin inhibitor was administered in most patients (66 of 69 patients 
who received second-line therapy). Therefore, a novel treatment approach, such as the use of 
nivolumab and not conventional targeted therapy, may be an effective treatment option for 
patients who have TLG as a component of PD after first-line TKI therapy failure.    
This study has several limitations. First, this study was retrospectively conducted in a single center, 
with a small cohort size. Thus, our results were affected by unavoidable biases of patient and 
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treatment selection. Second, our own TKI protocol may have influenced outcomes. That is, with 
regard to our use of sunitinib, a majority of patients received an alternative 2-weeks-on/1-week-
off schedule. Our previous study showed no significant difference in oncological outcome 
between this alternative schedule and the standard 4-weeks-on/1-week-off schedule [16]; however, 
we cannot deny that a possible influence on outcomes, caused by the difference of the regimens, 
might exist. Also, we selected either sorafenib or pazopanib for patients with poor general 
condition and, therefore, a corresponding selection bias may exist in some cases. Third, the 
RECIST can assess only the change of tumor diameter and not any intratumor activity, such as 
necrosis, which are considered to be important morphologic changes [25]. Therefore, the efficacy 
of TKI therapy might not be accurately reflected in some cases using the RECIST. Finally, there 
might be possible diagnostic bias among the components of PD. In particular, the definition of 
non-target lesion growth was likely to be less strict (unequivocal progression of existing non-
target lesions) compared to other components. Thus, the TLG or NLA might be over-diagnosed 
compared to NTLG, and this unbalanced priority of definition could affect the analyses.  
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5. Conclusions 
This retrospective single-center study identified TLG as an independent predictor of 
survival in patients with mRCC who received first-line TKI therapy. This finding is valuable for 
physicians with regard to predicting patient survival after first-line TKI therapy.  
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Figure legends 
Fig. 1 Progression-free survival according to the components of progressive disease   
Progression-free survival was compared between patients (A) with TLG and without TLG, (B) 
with NTLG and without NTLG, and (C) with NLA and without NLA.  
CI, confidence interval; TLG, target lesion growth; NTLG, non-target lesion growth; NLA, new 
lesion appearance 
 
Fig. 2 Overall survival according to components of progressive disease   
Overall survival was compared between patients (A) with TLG and without TLG, (B) with NTLG 
and without NTLG, and (C) with NLA and without NLA.  
CI, confidence interval; TLG, target lesion growth; NTLG, non-target lesion growth; NLA, new 
lesion appearance 
 
Fig. 3 Progression-free survival and overall survival in patients with target lesion growth (TLG) 
alone and new lesions appearance (NLA) alone (A). Progression free survival and (B) overall 
survival were compared between patients with TLG alone and NLA alone.  
CI, confidence interval  
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Electronic Supplementary Material Legends 
Electronic Supplementary Material 1. Flowchart of patient selection 
TKI, tyrosine kinase inhibitor 
 
Electronic Supplementary Material 2. (A) Progression-free survival and (B) overall survival 
for the entire study group.  
  
Electronic Supplementary Material 3. Overall survival after first-line therapy failure according 
to the components of progressive disease 
Overall survival after first-line tyrosine kinase inhibitor therapy failure was compared between 
patients (A) with or without TLG and (B) with TLG alone and NLA alone. 
TLG, target lesion growth; NLA, new lesion appearance 
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Table 1: Patient and tumor characteristics 
* Median and interquartile range 
MSKCC, Memorial Sloan Kettering Cancer Center; TLG, target lesion growth; NTLG, non-target 
Parameter N = 116 (%) 
Sex  
Male (ref. female) 82 (70.7) 
*Age 66 (60-71) 
Pathology  
   Clear cell carcinoma 84 (72.4) 
   Papillary renal cell carcinoma type 2 8 (6.9) 
   Clear cell carcinoma with spindle cell 8 (6.9) 
   Others/unknown 16 (13.8) 
First-line agent  
   Sorafenib 35 (30.2) 
   Sunitinib 73 (62.9) 
   Pazopanib 8 (6.9) 
Components of progression   
   TLG 80 (69.0) 
   NTLG 18 (15.5) 
   NLA 69 (58.6) 
   Only TLG  45 (37.9) 
   Only NTLG 0 (0) 
   Only NLA 36 (31.0) 
   With TLG and NTLG but not NLA 2 (1.7) 
   With TLG and NLA but not NTLG  17 (14.7) 
   With NTLG and NLA but not TLG 0 (0) 
   With TLG, NTLG, and NLA 16 (13.8) 
Prior nephrectomy  
   With  98 (84.5) 
   Without 18 (15.5) 
MSKCC risk classification  
   Favorable 17 (14.7) 
   Intermediate 81 (70.0) 
   Poor 18 (15.3) 
Metastatic lesions  
   Solitary  
   Multiple 40 (34.5) 
*Follow-up, months 19.4 (10.2-36.2) 
lesion growth; NLA, new lesion appearance 
   
Table 2: Univariate and multivariate analyses for progression-free survival 
Variable 
Univariate  
HR (95% CI) 
p 
Multivariate  
HR (95% CI) 
p 
Sex     
   Male Ref. - Ref. - 
   Female 1.73 (1.13-2.61) 0.0121 1.45 (0.92-2.23) 0.1059 
*Age, years 0.997 (0.98-1.01) 0.8   
Pathology     
CCC Ref. - Ref. - 
Non-CCC/unknown 2.25 (1.44-3.46) 0.0005 1.71 (1.04-2.75) 0.0526 
First-line agent     
   Sunitinib/Pazopanib Ref. -   
   Sorafenib 0.79 (0.52-1.68) 0.2406   
Components of progression      
   Without TLG Ref. - Ref. - 
   With TLG 1.77 (1.17-2.70) 0.0061 1.59 (1.02-2.51) 0.0395 
   Without NTLG Ref. - Ref. - 
   With NTLG 1.71 (1.00-2.78) 0.0515 1.73 (0.97-2.95) 0.0615 
   Without NLA Ref. -   
   With NLA 0.79 (0.55-1.16) 0.2306   
Prior nephrectomy     
   With  Ref. - Ref. - 
   Without 2.48 (1.43-4.07) 0.0018 2.07 (1.13-3.61) 0.0182 
MSKCC outcome classification     
   Favorable/intermediate Ref. - Ref. - 
   Poor 3.01 (1.74-4.95) 0.0002 3.22 (1.83-5.39) 0.0001 
Metastatic lesions     
   Solitary Ref. - Ref. - 
   Multiple 1.48 (0.98-2.14) 0.0649 1.34 (0.89-2.06) 0.1645 
* Continuous variable     
CCC, clear-cell carcinoma; HR, hazard ratio; CI, confidence interval; Ref, reference  
TLG, target lesion growth; NTLG, non-target lesion growth; NLA, new lesion appearance; MSKCC, 
Memorial Sloan Kettering Cancer Center 
Table 3: Univariate and multivariate analyses for overall survival 
Variable 
Univariate 
 HR (95% CI) 
p 
Multivariate  
HR (95% CI) 
p 
Sex     
   Male Ref. - Ref. - 
   Female 1.92 (1.21-3.02) 0.0066 1.73 (1.06-2.78) 0.0299 
*Age, years 0.997 (0.98-1.01) 0.8   
Pathology, %     
CCC Ref. - Ref. - 
Non-CCC/unknown 2.23 (1.35-3.60) 0.0023 1.99 (1.15-3.38) 0.0144 
First-line agent, %     
   Sunitinib/Pazopanib Ref. -   
   Sorafenib 0.84 (0.52-1.34) 0.4875   
Components of progression      
   Without TLG Ref. - Ref. - 
   With TLG 1.90 (1.18-3.16) 0.0073 1.67 (1.02-2.83) 0.04 
   Without NTLG Ref. -   
   With NTLG 1.54 (0.87-2.60) 0.1331   
   Without NLA Ref. -   
   With NLA 0.82 (0.54-1.28) 0.385   
Prior nephrectomy     
   With  Ref. - Ref. - 
   Without 2.18 (1.17-3.76) 0.0157 1.22 (0.62-2.28) 0.5468 
MSKCC outcome classification     
   Favorable/intermediate Ref. - Ref. - 
   Poor 2.73 (4.15-4.65) 0.0014 2.74 (1.48-4.80) 0.0019 
Metastatic lesions     
   Solitary Ref. - Ref. - 
   Multiple 2.40 (1.50-3.97) 0.0002 2.19 (1.36-3.66) 0.0012 
* Continuous variable     
CCC, clear-cell carcinoma; HR, hazard ratio; CI, confidence interval; Ref, reference 
TLG, target lesion growth; NTLG, non-target lesion growth; NLA, new lesion appearance; MSKCC, 
Memorial Sloan Kettering Cancer Center 
 
  
